Cosacthen 0.25 mg Solution is a Health Canada–registered veterinary drug (DIN 02498405) held by Dechra Ltd, containing Tetracosactide. Health Canada lists its status as Marketed (status date 13 Oct 2020). Nexara Health has matched 20 registrations of Tetracosactide across 14 other regulated markets.
Health Canada registration
| DIN | 02498405 |
|---|---|
| Brand name | Cosacthen |
| Active ingredient | Tetracosactide |
| Strength | 0.25 mg |
| Dosage form | Solution |
| Route | Intramuscular ; Intravenous |
| Company | Dechra Ltd |
| Status | Marketed — 13 Oct 2020 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Tetracosactide registered in other markets
20 registrations of the same molecule in 14 national registries outside Canada. Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Australia | Synacthen Depot 1 mg/1 mL | Ix | Compound depot injection 1 mg in 1 mL | GE | PBS | |
| Denmark | Synacthen | Alfasigma S.p.A | 0,25 mg/ml | injektionsvæske, opløsning | National | Laegemiddelstyrelsen |
| Denmark | Synacthen | CD Pharmaceuticals AB | 0,25 mg/ml | injektionsvæske, opløsning | Par-Imp | Laegemiddelstyrelsen |
| Iceland | Synachten | Parlogis - óskráð lyf | 0,25 mg/ml | stl | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Synachten | Vistor - óskráð | 0,25 mg/ml | stl | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Synachten | Parlogis - óskráð lyf | 0,25 mg/ml | stl | 0 | Lyfjastofnun lyfjaverdskra |
| Ireland | Synacthen 250 micrograms/ml solution for injection | Alfasigma S.p.A | Solution for injection | Marketed | HPRA | |
| Luxembourg | Synacthen SOL.INJ. 0,25 mg / 1 mL 1*1 ampoule verre 1 mL | — | RR | CNS liste positive | ||
| MA | Synacthene | — | 1 MG | Suspension Injectable | P | CNOPS liste des medicaments |
| Malta | Synacthen Ampoules 250mcg | Central Procurement & Supplies Unit | Solution For Infusion Or Injection | Authorised | Medicines Authority | |
| Netherlands | Synacthen 0,25 mg/ml, oplossing voor injectie of infusie | Alfasigma S.p.A. | Oplossing voor injectie of infusie | Uitsluitend recept | EU national register | |
| Poland | Cosacthen | Dechra Regulatory B.V. | 0,25 mg/ml | Roztwór do wstrzykiwań | Bezterminowe | URPL RPL |
| Romania | SYNACTHEN 0,25 mg/1ml | — | 0,25mg/1ml | Sol. Inj. | PR _x0002_ | ANMDMR nomenclator |
| Saudi Arabia | Synacthen Depot | — | 1 | Inactive | SFDA | |
| Saudi Arabia | Synacthen Depot | — | 1 | Inactive | SFDA | |
| South Africa | Synacthen | Novartis South Africa (Pty) Ltd | 1 mg/ml | Inj | S4 | DoH SEP database |
| United Kingdom | Tetracosactide 1mg/1ml suspension for injection ampoules | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Tetracosactide 250micrograms/1ml solution for injection ampoules | — | 0001 | NHS dm+d VMP | ||
| United States | Tetracosactide | BCN Peptides SA | Powder | FDA NDC | ||
| United States | Tetracosactide | Bachem AG | Powder | FDA NDC |
See every manufacturer of Tetracosactide worldwide →
Regulator price references for Tetracosactide
Published list or reimbursement prices for Tetracosactide presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Australia | Synacthen Depot 1 mg/1 mL | 1mg/1ml | Compound depot injection 1 mg in 1 mL | 53.20 AUD | ex-manufacturer | PBS | 2026-09-08 |
| Iceland | Synachten | 0.25mg/1ml | stk | 3,825.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Synachten | 0.25mg/1ml | stk | 3,834.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Synachten | 0.25mg/1ml | stk | 30,225.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Luxembourg | Synacthen SOL.INJ. 0,25 mg / 1 mL 1*1 ampoule verre 1 mL | 0.25mg/1ml | 7.81 EUR | reimbursement | CNS liste positive | 2026-09-05 | |
| MA | Synacthene | 1mg | 1 BOITE 1 AMPOULE INJECTABLE | 47.30 MAD | PPV (public price) | CNOPS liste des medicaments | 2026-09-05 |
| Saudi Arabia | Synacthen Depot | 20.00 SAR | public | SFDA | 2026-09-01 | ||
| Saudi Arabia | Synacthen Depot | 1,698.00 SAR | public | SFDA | 2026-09-01 | ||
| South Africa | Synacthen | 1mg/1ml | 1 | 479.16 ZAR | single exit price | DoH SEP database | 2026-09-01 |
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Cosacthen (DIN 02498405) marketed in Canada?
Yes. Health Canada lists DIN 02498405 as Marketed as of 13 Oct 2020.
Who holds the Canadian licence for this product?
Dechra Ltd is the company of record in the Health Canada Drug Product Database.
Is Tetracosactide registered outside Canada?
Yes — Nexara Health has matched 20 registrations in 14 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02498405, status date 2020-10-13; national medicine registries: ANMDMR nomenclator, CNOPS liste des medicaments, CNS liste positive, DoH SEP database, EU national register, FDA NDC, HPRA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, URPL RPL; price sources: CNOPS liste des medicaments, CNS liste positive, DoH SEP database, Lyfjastofnun lyfjaverdskra, PBS, SFDA. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02498405, status date 2020-10-13; national medicine registries: ANMDMR nomenclator, CNOPS liste des medicaments, CNS liste positive, DoH SEP database, EU national register, FDA NDC, HPRA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, URPL RPL; price sources: CNOPS liste des medicaments, CNS liste positive, DoH SEP database, Lyfjastofnun lyfjaverdskra, PBS, SFDA.
Health Canada Drug Product Database (DPD), DIN 02498405, status date 2020-10-13; national medicine registries: ANMDMR nomenclator, CNOPS liste des medicaments, CNS liste positive, DoH SEP database, EU national register, FDA NDC, HPRA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, URPL RPL; price sources: CNOPS liste des medicaments, CNS liste positive, DoH SEP database, Lyfjastofnun lyfjaverdskra, PBS, SFDA. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.